Comparison of Conservative and Endovascular Treatment for Spontaneously Isolated Superior Mesenteric Artery Dissection

Comparison of Conservative and Endovascular Treatment for Spontaneously Isolated Superior Mesenteric Artery Dissection: A Real-world, Multicenter, Observational Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05342233

Enrollment

200

Registered

2022-04-22

Start date

2022-04-30

Completion date

2028-04-01

Last updated

2022-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spontaneous Isolated Superior Mesenteric Artery Dissection

Brief summary

Spontaneous isolated superior mesenteric artery dissection(SISMAD) is an increasingly diagnosed disease. However, prospective, multicenter studies that can provide evidence to support clinical decisions are very limited. This study aims to compare the therapeutic efficacy of conservative and endovascular treatment for SISMAD.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Aged 18 and above; 2. Isolated superior mesenteric artery dissection with clear symptoms or history and confirmed by CTA 3. Signed informed consent forms, willing to receive treatments

Exclusion criteria

1. Symptoms are severe and patients need exploratory laparotomy; 2. Patients with aortic dissection, iliac artery dissection, or autoimmune vasculitis; 3. Patients with mental illness cannot cooperate subjectively; 4. Patients who are allergic to contrast agents, or contraindicated to conservative treatment drugs, and cannot be treated with drugs; 5. Pregnancy and breastfeeding women, or patients who have recent birth plans; 6. Patients who are participating in other clinical projects; 7. Patients are not suitable to participate in this study.

Design outcomes

Primary

Measure	Time frame	Description
Mortality	up to 5 years	Mortality during follow-up period
Rate of symptom relief	up to 5 years	Rate of symptom relief during follow-up period

Secondary

Measure	Time frame	Description
Reintervention rate	Follow-up period（ 5 years）	Reintervention related to SISMAD after treatments during follow-up period
Recurrence rate	Follow-up period（5 years）	SISMAD Recurrence after treatments during follow-up period
Disease-related complications	Follow-up period（5 years）	Disease-related complications after treatments during follow-up period
Complete remodeling rate of superior mesenteric artery dissection	Follow-up period（5 years）	Complete remodeling rate of superior mesenteric artery dissection after receiving different treatments

Countries

China

Contacts

Primary ContactWang WEI, Ph.D.

weiwangcsu@csu.edu.cn13808482650

Outcome results